We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ono and Galapagos Sign an Additional Target Discovery Agreement
News

Ono and Galapagos Sign an Additional Target Discovery Agreement

Ono and Galapagos Sign an Additional Target Discovery Agreement
News

Ono and Galapagos Sign an Additional Target Discovery Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ono and Galapagos Sign an Additional Target Discovery Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV and Ono Pharmaceutical Co., Ltd. have announced that they have signed an additional collaboration agreement focused on discovering novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma.

In the new agreement, Galapagos’ service division BioFocus will use its SilenceSelect® platform to deliver validated targets to Ono.

Ono aims to find modulators for these targets and generate novel drug candidates. Financial details were undisclosed.

“We are delighted with the success of our relationship with Ono,” said Dr Chris Newton, SVP Galapagos Services and Managing Director BioFocus.

Dr Newton continued, “The start of a new collaboration one year after the first one is testament to our target discovery platform and the strength of our partnership.”

Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono commented: “This new project builds upon a novel human primary cell-based assay developed by BioFocus in the field of allergic diseases, an area with significant unmet medical needs. We are excited to apply BioFocus’ target discovery platform to discover and validate novel drug targets.”

Advertisement